Interferon therapy of chronic hepatitis B

Intervirology

Volumn 57, Issue 3-4, 2014, Pages 163-170

  Brunetto, Maurizia Rossana ^a   Bonino, Ferruccio ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

Chronic hepatitis B; Chronic hepatitis B treatment; HBsAg quantification; Hepatitis B virus DNA; Immune response; Interferon

Indexed keywords

ALPHA INTERFERON; HEPATITIS B SURFACE ANTIGEN; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA; RIBAVIRIN; VIRUS RNA; VIRUS DNA; ANTIVIRUS AGENT; HEPATITIS B(E) ANTIGEN; IMMUNOLOGIC FACTOR; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN;

ADAPTIVE IMMUNITY; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; GENETIC POLYMORPHISM; HEPATITIS B; HUMAN; INNATE IMMUNITY; MINICHROMOSOME; PERSONALIZED MEDICINE; PRIORITY JOURNAL; VIRUS REPLICATION; DRUG MECHANISM; EPIGENETICS; IMMUNE RESPONSE; NONHUMAN; BLOOD; CD8+ T LYMPHOCYTE; DRUG EFFECTS; GENETICS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; IMMUNOLOGY; METABOLISM;

HEPATITIS B VIRUS;

ANTIVIRAL AGENTS; CD8-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; VIRUS REPLICATION;

EID: 84904670384     PISSN: 03005526     EISSN: 14230100     Source Type: Journal    
DOI: 10.1159/000360941     Document Type: Article

References (47)

1. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2012; 57: 167-185.
2. Carosi G, Rizzetto M, Alberti A, Cariti G, Colombo M, Craxi A, Filice G, Levrero M, Mazzotta F, Pastore G, Piccinino F, Prati D, Raimondo G, Sagnelli E, Toti M, Brunetto MR, Bruno R, Di Marco V, Ferrari C, Gaeta GB, Lampertico P, Marzano A, Pollicino T, Puoti M, Santantonio T, Smedile A: Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop. Dig Liver Dis 2011; 43: 259-265.
3. Iannazzo S, Coco B, Brunetto MR, Rossetti F, Caputo A, Latour A, Espinos B, Bonino F: Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-2a as first-line and week-12 HBV DNA/ HBsAg stopping rule: a cost-effectiveness analysis. Antivir Ther 2013; 18: 623-633.
4. Sung JJ, Tsoi KK, Wong VW, et al: Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2009; 28: 1067-1077.
5. Wong GL, Yiu KK, Wong VW, et al: Metaanalysis: Reduction in hepatic events following interferon-alfa. Ther Chronic Hepatitis B 2010; 32: 1059-1068.
6. Borden EC, Sen GC, Uze G, et al: Interferons at age 50: past, current and future impact on biomedicine. Nat Rev 2007; 6: 975-990.
7. Sadler AJ, Williams BR: Interferon-inducible antiviral effectors. Nat Rev Immunol 2008; 8: 559-568.
8. Wieland SF, Guidotti LG, Chisari FV: Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol 2000; 74: 4165-4173.
9. Xu C, et al: Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus. J Virol 2010; 84: 9332-9340.
10. Li J, et al: Inhibition of hepatitis B virus replication by MyD88 involves accelerated degradation of pregenomic RNA and nuclear retention of pre-S/S RNAs. J Virol 2010; 84: 6387-6399.
11. Xia Y, Lucifora J, Zhang K, Cheng X, Stadler D, Reisinger F, Feuerherd M, Heikenwalder M, Protzer U: Interferons induce degradation of HBV cccDNA. AASLD 2013:A133.
12. Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, Petersen J, Raimondo G, Dandri M, Levrero M: IFN inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest 2012; 122: 529-537.
13. Rehermann B: Immune response in hepatitis B virus infection. Semin Liver Dis 2003; 23: 21-23.
14. Thimme R, Dandri M: Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B? J Hepatol 2013; 58: 205- 209.
15. Boni C, Laccabue D, Lampertico P, Giuberti T, Vigano M, Schivazappa S, Alfieri A, Pesci M, Gaeta GB, Brancaccio G, Colombo M, Missale G, Ferrari C: Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 2012; 143: 963-973.
16. Penna A, Laccabue D, Libri I, Giuberti T, Schivazappa S, Alfieri A, Mori C, Canetti D, Lampertico P, Vigano M, Colombo M, Loggi E, Missale G, Ferrari C: Peginterferon does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis. J Hepatol 2012; 56: 1239- 1246.
17. Micco L, Peppa D, Loggi E, Schurich A, Jefferson L, Cursaro C, Panno AM, Bernardi M, Brander C, Bihl F, Andreone P, Maini MK: Differential boosting of innate and adaptive antiviral responses during pegylated-interferon- alpha therapy of chronic hepatitis B. J Hepatol 2013; 58: 225-233.
18. Carotenuto P, Artsen A, Niesters HG, Osterhaus AD, Pontesilli O: In vitro use of autologous dendritic cells improves detection of T cell responses to hepatitis B virus (HBV) antigens. J Med Virol 2009; 81: 332-339.
19. Jilg N, Chung RT: One more piece in the interleukin 28B gene puzzle? The case of hepatitis B. Hepatology 2013; 57: 870-872.
20. Tseng TC, Yu ML, Liu CJ, Lin CL, Huang YW, Hsu CS, Liu CH, Kuo SF, Pan CJ, Yang SS, Su CW, Chen PJ, Chen DS, Kao JH: Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-2a therapy. Antivir Ther 2011; 16: 629-637.
21. Craxi A, Di Bona D, Camma C: Interferon for HBeAg-positive chronic hepatitis B. J Hepatol 2003; 39:S99-S105.
22. Brunetto MR, Oliveri F, Colombatto P, Coco B, Ciccorossi P, Bonino F: Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon. J Hepatol 2003; 39(Suppl 1):S164-S167.
23. Manesis EK, Hadziyannis SJ: Interferon alpha treatment and retreatment of hepatitis B e antigen- negative chronic hepatitis B. Gastroenterology 2001; 121: 101-109.
24. Brunetto MR, Oliveri F, Coco B, et al: Outcome of anti-HBe positive chronic hepatitis in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36: 263-270.
25. Lampertico P, Del Ninno E, Vigano M, et al: Long-term suppression of hepatitis B e antigen- negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003; 37: 756- 763.
26. Fattovich G, Bortolotti F, Donato F: Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335-352.
27. Tossing G: New developments in interferon therapy. Eur J Med Res 2001; 6: 47-65.
28. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N; Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group: Peginterferon alfa-2a, lamivudine, and the combination for HBeAgpositive chronic hepatitis B. N Engl J Med 2005; 352: 2682-2695.
29. Piratvisuth T, Lau G, Chao YC, Jin R, Chutaputti A, Zhang QB, Tanwandee T, Button P, Popescu M: Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol Int 2008; 2: 102-110.
30. Marcellin P, Bonino F, Yurdaydin C, Hadziyannis S, Moucari R, Kapprell HP, Rothe V, Popescu M, Brunetto MR: Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. Hepatol Int 2013; 7: 88-97.
31. Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Brunetto MR, Farci P, Popescu M, McCloud P; Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group: Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56: 699-705.
32. Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, So TM, Feinman SV, Mach T, Akarca US, Schutten M, Tielemans W, van Vuuren AJ, Hansen BE, Janssen HL: Sustained HBeAg and HBsAg loss after longterm follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008; 135: 459-467.
33. Erhardt A, Reineke U, Blondin D, Gerlich WH, Adams O, Heintges T, Niederau C, Haussinger D: Mutations of the core promoter and response to interferon treatment on chronic hepatitis B. Hepatology 2000; 31: 716- 725.
34. Lobello S, Lorenzoni V, Vian A, Floreani A, Brunetto MR, Chiaramonte M: Interferon treatment in HBsAg positive anti-HBe positive chronic hepatitis B: role of hepatitis B core antibody IgM titre in patients selection and treatment outcome. J Viral Hepat 1998; 1: 61-66.
35. Brunetto MR, Moriconi F, Bonino F, et al: Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141-1150.
36. Brunetto MR: A new role for an old marker J. Hepatol 2010; 52: 475-477.
37. Sonneveld MJ, Rijckborst V, Boucher CA, et al: Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010; 52: 1251-1257.
38. Moucari R, Mackiewicz V, Lada O, et al: Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151-1157.
39. Brunetto MR, Marcellin P, Cherubini B, Yurdaydin C, Farci P, Hadziyannis SJ, Rothe V, Regep L, Bonino F: Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: Ontreatment kinetics of HBsAg serum levels vary by HBV genotype. J Hepatol 2013; 59: 1153-1159.
40. Sonneveld MJ, Hansen BE, Piratvisuth T, Jia JD, Zeuzem S, Gane E, Liaw YF, Xie Q, Heathcote EJ, Chan HL, Janssen HL: Responseguided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology 2013; 58: 872-880.
41. Brunetto MR, Oliveri F, Colombatto P, et al: Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010; 139: 483-490.
42. Rijckborst V, Hansen BE, Ferenci P, Brunetto MR, Tabak F, Cakaloglu Y, Lanza AG, Messina V, Iannacone C, Massetto B, Regep L, Colombo M, Janssen HL, Lampertico P: Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol 2012; 56: 1006-1011.
43. Chudy M, Scheiblauer H, Hanschmann K-M, Kress J, Nick S, Wend U, Schuttler C, Nubling CM, Gerlich WH: Performance of hepatitis B surface antigen tests with the first WHO international hepatitis B virus genotype reference panel. J Clin Virol 2013; 58: 47-53.
44. Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, Tang H, Sheng J, Zhao M: Patients with HBeAg-positive chronic hepatitis B (CHB) with a maintained virological response to entecavir achieved HBsAg clearance when switched to peginterferon alfa-2a therapy (the OSST study). AASLD 2012:A121.
45. Ouzan D, Penaranda G, Joly H, Khiri H, Pironti A, Halfon P: Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs. J Clin Virol 2013; 58: 713-717.
46. Bonino F, Lau GKK, et al: On treatment HBsAg decline in HBeAg-negative patients as a predictor of response to Peg-Interferon alfa- 2a (40 kd) therapy 3 years post-treatment: potential for response guided therapy. J Hepatol 2008;48:S254.
47. Brunetto MR, Cavallone D, Moriconi F, et al: Kinetics of HBsAg decline during and following treatment of CHB: early and rapid HBsAg decline during Peg-Interferon alfa-2a is predictive of HBsAg clearance. Hepatology 2008;48:717A-718A.